4:07 PM ET
10-Q
Financial Results
Immix Biopharma Q3 2026 Results: Net Loss of $13.9M, Loss Widens
Immix Biopharma, Inc. reported a significant increase in cash and cash equivalents to $320.3 million as of September 30, 2026, compared to $93.9 million at year-end 2025. The company's accumulated deficit grew to $140.0 million, driven by nine-month operating expenses including $22.4 million in general and administrative costs and $16.9 million in research and development.
- Key figure
- Net loss $13.9M